QIMR Berghofer researchers have discovered a potential new cancer immunotherapy target that involves switching off a regulatory cell to stop tumours growing and spreading.
The study findings have been published today in Cancer Discovery, a journal of the American Association for Cancer Research.
Senior researcher and head of QIMR Berghofer’s Cancer Immunoregulation and Immunotherapy Laboratory, Associate Professor Michele Teng, said in future the discovery could potentially help treat patients with cancers where other current immunotherapies have not worked.
“Our work on mice shows for the first time that many tumours display the molecule MR1 on their cell surface, and when it’s present, this molecule turns on an important regulatory cell that prevents the body’s own immune system from fighting the cancer,” Associate Professor Teng said.
“We found if a type of regulatory cell called MAIT (mucosal-associated invariant T) cells are turned on, they stop immune or white blood cells known as T and NK cells from attacking and killing off tumour cells.
“The cancer is effectively creating its own defence mechanism to evade immune attack and survive. The display of MR1 activates the MAIT cells, which in turn switch off cancer-fighting T and NK cells.
“While other regulatory cells of the immune system are known to stop T and NK cells from killing tumour cells, this is the first time it’s been shown that these regulatory MAIT cells can do this job.”
Associate Professor Teng said her team found that by giving mice an antibody that blocked MR1, this stopped the MAIT cells from becoming activated, and the T and NK cells could respond, slowing cancer growth and stopping it spreading.
“This work demonstrates that antibodies that block MR1 could in future be an effective new immunotherapy,” Associate Professor Teng said.
“It probably won’t work on every cancer, but it looks like it could be effective in treating cancers that can display the MR1 molecule. It also means this display of MR1 could be used to screen which patients would respond to this immunotherapy.
“We now need to replicate this research in humans.”
Associate Professor Teng said while the research was at a very early stage and required more work, it was promising.
“The next step is to try to understand what kind of human tumours display MR1 as a protective mechanism, which would then help us identify which tumours would respond best to MR1-blocking immunotherapy,” she said.
“Immunotherapies have been effectively used to treat more than 15 different cancer types but the proportion of patients that respond for each cancer can differ.
“In patients with advanced melanoma for example, current approved immunotherapies work in about 50 per cent of cases, but half do not respond, and that’s why we need to find new therapies.”
Learn more: POTENTIAL NEW CANCER TREATMENT A STEP CLOSER
Go deeper with Bing News on:
- Dexamethasone May Be Detrimental to Immunotherapy in Glioblastoma Patientson November 25, 2020 at 12:00 pm
Historically, patients with glioblastoma have been empirically treated with dexamethasone, even without symptoms, with many clinicians prescribing steroids for prolonged periods of time, out of a ...
- Why Immunotherapy Only Works for Some Patients With Head and Neck Canceron November 24, 2020 at 4:00 pm
Researchers have discovered new clues into why some people with head and neck cancer respond to immunotherapy, while others don't.
- Why immunotherapy only works for some with head and neck canceron November 24, 2020 at 6:27 am
University of Cincinnati researchers have discovered new clues into why some people with head and neck cancer respond to immunotherapy, while others don't.
- Global Cancer Immunotherapy Drug Discovery Outsourcing Market 2020 Size, Market Share, Key Players, Segmentation Development and Forecast by 2026on November 24, 2020 at 2:03 am
MarketsandResearch.biz has newly published research study entitled Global Cancer Immunotherapy Drug Discovery Outsourcing Market 2020 by Company, Regions, Type and Application, Forecast to 2026 that ...
- Global cancer immunotherapy market size to reach USD 117.82 billion by 2026on November 24, 2020 at 2:00 am
According to industry experts, global cancer immunotherapy market size is projected to reach USD 117.82 billion by the year 2026. Spike in the number of cases of cancer and associated deaths is ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Allergy Immunotherapy Market Size to record 10.85% CAGR over 2020-2027on November 25, 2020 at 5:26 am
Global Allergy Immunotherapy Market is valued approximately USD 2.9 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10.85% over the forecast period 2020-2027.
- Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Meton November 24, 2020 at 3:59 am
First immunotherapy to be approved for a gastroesophageal cancer in the European UnionApproval based on Phase 3 ATTRACTION-3 trial showing statistically significant and clinically meaningful ...
- Carbon ions team up with immunotherapy to tackle advanced tumourson November 24, 2020 at 2:34 am
Carbon-ion radiotherapy combined with immune checkpoint inhibitors could offer a promising new approach for treatment of metastatic cancer ...
- New type of immunotherapy may pave way for better cancer treatmentson November 23, 2020 at 11:24 pm
Immunotherapy for cancer has made great advances and many patients can now receive effective treatments that were not available ten years ago.
- Experimental cancer vaccine passes animal tests, moves to human trialson November 23, 2020 at 7:38 pm
A novel cancer vaccine is moving to Phase 1 human trials in the United States after promising results from animal studies showed encouraging efficacy and a robust safety profile. A new study describes ...